AEX:ONWD

ONWARD Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation after Spinal Cord Injury

Retrieved on: 
Thursday, December 8, 2022
Professional Services, Health, Surgery, Finance, Managed Care, Pharmaceutical

ARC Therapy immediately improved blood pressure levels for all participants; this benefit has been sustained for the duration of the current follow-up period.

Key Points: 
  • ARC Therapy immediately improved blood pressure levels for all participants; this benefit has been sustained for the duration of the current follow-up period.
  • The results reported today with ARC Therapy are compelling and may open a new avenue to help people with spinal cord injury truly feel better, while also addressing heart health.
  • The interim outcomes reported today are from ten people with spinal cord injury who were treated at clinical centers in Canada and Switzerland.
  • Over 40% of people with spinal cord injury, or approximately 262,000 people in the U.S. and Europe2, are estimated to experience hypotension, or low blood pressure.

ONWARD Awarded European Innovation Council Grant to Further Develop Brain-Computer Interface Technology; Company also Wins First Place in 2022 Brain-Computer Interface Awards

Retrieved on: 
Monday, November 21, 2022
Medical Devices, Health, Other Health, Research, Science, Biotechnology, University of California, San Francisco, EUR, CHUV, Euronext, Partnership, Materials Research Science and Engineering Centers, In the First Place, International, SCI, Interface (computing), Stanford University, Swiss Federal Institute of Aquatic Science and Technology, Loss of Sensation, Science, EIC, Quality of life, Spinal cord injury, Hyperreflexia, U.S. FDA, Pathfinder, EPFL, Swiss Federal Institute of Technology, Research, Spinal cord, Paralysis, Nature, Incontinence, Paraplegia, ARC, Record, European Innovation Council, Tetraplegia, Lausanne University Hospital, University, BCI, Movement, Infection, Hope, Health, NEMO, Brain–computer interface, Medical device, Pharmaceutical industry

Separately, ONWARD announced that it was the First Place Winner of the 2022 Brain-Computer Interface (BCI) Award .

Key Points: 
  • Separately, ONWARD announced that it was the First Place Winner of the 2022 Brain-Computer Interface (BCI) Award .
  • The award was granted to ONWARD and several research partners for their submission, Walking naturally after spinal cord injury using a brain-spine interface.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

ONWARD’s Research Partner .NeuroRestore Publishes Groundbreaking Paper Identifying Neurons that Restore Walking after Paralysis

Retrieved on: 
Thursday, November 10, 2022
Health, Medical Devices, Neurology, Health Technology, Research, Science, Biotechnology, Quality of life, ARC, Forward-looking statement, Health, Partnership, Research, CHUV, Technology, Swiss Federal Institute of Technology, Spinal cord, Neuron, Science, Leg, Spinal cord injury, Lausanne University Hospital, Muscle, SCI, Movement, Company, Program, Walking, Materials Research Science and Engineering Centers, Euronext, Hyperreflexia, EPFL, CEO, U.S. FDA, Swiss Federal Institute of Aquatic Science and Technology, Paralysis, Medical device, Trapping, Nature

The findings published yesterday continue to build our strong knowledge base in spinal cord stimulation to help people with paralysis.

Key Points: 
  • The findings published yesterday continue to build our strong knowledge base in spinal cord stimulation to help people with paralysis.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • ONWARDs work builds on more than a decade of basic science and preclinical research conducted at the worlds leading neuroscience laboratories.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

ONWARD Reports Third Quarter 2022 Highlights and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022
Medical Devices, Health, FDA, Research, Science, Biotechnology, ARC, Company, Program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Health, Spinal cord, EUR, Quality of life, U.S. FDA, Government, Director, CHUV, Swiss Federal Institute of Aquatic Science and Technology, Arm, Forward-looking statement, Partnership, SIX Financial Information, Webcast, Lausanne University Hospital, FDA, Nature, Public, EPFL, McKinsey & Company, Science, Spinal cord injury, Safety, Technology, CEO, SCI, Food, Movement, Diagnosis, Physician, Swiss Federal Institute of Technology, CET, Patient, Board, Neurogenic bladder dysfunction, Euronext, NIH, Investment, Hemiunu, Marketing, Hyperreflexia, Medical device, Pharmaceutical industry, Tutoring, Risk management, EU, Zoom

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today discussed highlights from the third quarter of 2022 and provided a business update.

Key Points: 
  • ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today discussed highlights from the third quarter of 2022 and provided a business update.
  • In September 2022, ONWARD reported positive top-line results from its Up-LIFT pivotal study evaluating transcutaneous stimulation with its external ARC Therapy.
  • In October 2022, ONWARD reported topline results from the LIFT Home study, evaluating the safety and feasibility of ARC-EX Therapy when used at home.
  • In September 2022, ONWARD appointed Vivian Riefberg, a highly accomplished expert in healthcare, government, and strategy, to the Board of Directors.

ONWARD Schedules Webcast to Provide Third Quarter Business Update and Announces Participation at Upcoming Conferences

Retrieved on: 
Thursday, October 27, 2022
Software, Finance, Hardware, Health, Medical Devices, Health Technology, Professional Services, Technology, Science, Spinal cord injury, Swiss Federal Institute of Aquatic Science and Technology, CET, Nature, U.S. FDA, Movement, Swiss Federal Institute of Technology, Technology, Quality of life, Company, Partnership, Spinal cord, EPFL, Lausanne University Hospital, ARC, Health, CHUV, Medical device, Risk management

Lara Smith Weber will give a company presentation and be available for questions together with Markus Rieger, Field Clinical Specialist.

Key Points: 
  • Lara Smith Weber will give a company presentation and be available for questions together with Markus Rieger, Field Clinical Specialist.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • ONWARDs work builds on more than a decade of basic science and preclinical research conducted at the worlds leading neuroscience laboratories.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

ONWARD Announces Topline Results from the LIFT Home Study Supporting Safety and Feasibility of ARC-EX Therapy to Treat People with Spinal Cord Injury at Home

Retrieved on: 
Wednesday, October 5, 2022
Research, Medical Devices, Finance, Professional Services, Other Health, Biotechnology, Physical Therapy, General Health, Health, Science, Quality of life, Incontinence, Euronext, Movement, Spinal cord, PT, Infection, Science, U.S. FDA, Patient, Loss of Sensation, High Tech Campus Eindhoven, NCS, Technology, University, Company, SCI, Health, CEO, Nature, Afghanistan Research and Evaluation Unit, DPT, Safety, Evaluation, Spinal cord injury, Forward-looking statement, University of Minnesota, ARC, Paralysis, University of Washington Department of Bioengineering, Pharmaceutical industry, Risk management, Medical device, Research, Shepherd Center

ARC-EX Therapy is a proprietary non-invasive spinal cord stimulation technology designed to restore movement and other functions in people with spinal cord injury (SCI) and other movement disabilities.

Key Points: 
  • ARC-EX Therapy is a proprietary non-invasive spinal cord stimulation technology designed to restore movement and other functions in people with spinal cord injury (SCI) and other movement disabilities.
  • The main objective of the study is to evaluate the safety and feasibility of ARC-EX Therapy when used at home.
  • The absence of any device-related adverse events confirmed the favorable safety results observed during the Up-LIFT Study when ARC-EX Therapy was used in clinics.
  • Approximately 7 million people globally have a spinal cord injury, with over 650,000 in the U.S. and Europe alone.

ONWARD Announces Participation at Upcoming Events in October

Retrieved on: 
Thursday, September 29, 2022
Science, Neurology, Biotechnology, Research, Physical Therapy, Health, Medical Devices, Health Technology, Health, Marver, Movement, High Tech Campus Eindhoven, U.S. FDA, Spinal cord, Spinal cord injury, Nature, Company, CEO, Technology, Quality of life, Science, ARC, Medical device, Risk management

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.

Key Points: 
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • ONWARD has received three Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IMand ARC-EX.
  • These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Spinal Cord Stimulation Delivers Improved Arm Function

Retrieved on: 
Thursday, June 30, 2022
Health, Surgery, Clinical Trials, Research, Science, Biotechnology, FDA, Science, Movement, CEO, Neuroscience, Company, High Tech Campus Eindhoven, Nature Neuroscience, EPFL, Euronext, Hand, Technology, FES, Fatigue, Health, Quality of life, Human, Spinal cord injury, Nature, ARC, Dentistry, Medical device

Regaining hand and arm function is the highest priority for many people with cervical spinal cord injury.

Key Points: 
  • Regaining hand and arm function is the highest priority for many people with cervical spinal cord injury.
  • Researchers in todays Nature Neuroscience publication investigated a potentially more effective approach to improving motor control of the upper limbs after spinal cord injury an implantable neurostimulation system that modulates the spinal cord region involved in controlling hand and arm function.
  • This preclinical data showed that precise electrical stimulation targeting relevant spinal cord segments enhanced muscle activation and strength, and facilitated more efficient hand and arm movements.
  • As part of its suite of intellectual property agreements with EPFL, ONWARD has the rights to develop and commercialize cervical spinal cord stimulation therapy to improve hand and arm function in people with spinal cord injury.

ONWARD Awarded European Innovation Council Grant to Develop Brain-Spine Interface Technology

Retrieved on: 
Thursday, June 16, 2022
Medical Devices, Health, Managed Care, Research, Science, Biotechnology, Spinal cord, ARC, FDA, High Tech Campus Eindhoven, Interface, Science, BSI, Technology, European Innovation Council, Rehabilitation, CEO, Company, Research, SCI, Neurodegeneration, EPFL, Professor, EUR, Health, Record, Quality of life, Nature, Edmond, Euronext, IP, Spinal cord injury, Movement, Diagnosis, Hyperreflexia, Multimedia, EIC, Physical, Medical device

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today announces it has been awarded a grant from the European Innovation Council (EIC) to support the development of an innovative Brain-Spine Interface technology for restoring mobility and upper limb function.

Key Points: 
  • ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today announces it has been awarded a grant from the European Innovation Council (EIC) to support the development of an innovative Brain-Spine Interface technology for restoring mobility and upper limb function.
  • This grant from the EIC validates ONWARDs position as a leader in the fast emerging realm of Brain-Spine Interface technologies, said Dave Marver, CEO of ONWARD.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

ONWARD Announces New Board Appointment

Retrieved on: 
Monday, June 13, 2022
Professional Services, Health, Medical Devices, Finance, Research, Science, Biotechnology, Science, ARC, Euronext, Company, Board of directors, High Tech Campus Eindhoven, GlaxoSmithKline, Johns Hopkins University, CEO, Nature, London School of Economics, Philosophy, politics and economics, University of Göttingen, London, Business administration, Multimedia, Hyperreflexia, International economics, University of Oxford, FDA, Growth, Master of Science, Spinal cord injury, Technology, Health, Movement, Quality of life, Judgement, Industry, Behavioral health outcomes management, National College of Business Administration and Economics, Pharmaceutical industry, Risk management, Politics, Economics, Philosophy, Health policy

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the appointment of Kristina Dziekan to its Board of Directors.

Key Points: 
  • ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces the appointment of Kristina Dziekan to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20220613005579/en/
    Kristina strengthens our Board, bringing judgment and expertise needed for our next phase of growth, said Dave Marver, CEO of ONWARD.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX.